Chinese Journal of Organic Chemistry >
Synthesis and Antitumor Activity Evaluation of 2,4,6-Trisubstituted Pyrimidine Derivatives
Received date: 2017-05-08
Revised date: 2017-05-23
Online published: 2017-06-07
Supported by
Project supported by the National Natural Science Foundation of China (No.81430085) and the Research Project of Science and Technology Bureau of Zhengzhou City (No.141PQYJS554).
With the aim of obtaining potential antitumor candidates with more efficiency and more economic value. 40 2,4,6-trisubstituted pyrimidine derivatives bearing chalcone moiety were synthesized via cyclization, chlorination, substitution with benzoylacetate and ethylacetoacetate as the starting materials. The structures of target products were confirmed by 1H NMR, I3C NMR and HRMS. 2,4,6-Trisubstituted pyrimidine derivatives bearing chalcone moiety were evaluated for anticancer activity on four human cancer cell lines including EC-109, MGC-803, HepG-2 and MDA-MB-231 by CCK-8 (cell counting Kit-8) assay. Among them, (E)-1-(4-((2-(((1H-benzo[d]imidazol-2-yl)methyl)thio)-6-methylpyrimidin-4-yl)amino)-phe-nyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (13u) were more cytotoxic against MGC-803 and MDA-MB-231 cell lines, with IC50 values of 0.99 and 1.77 μmol·L-1, respectively.
Key words： 2,4,6-trisubstituted pyrimidine; chalcone; antitumor
Song Panpan , Li Na , Cui Fei , Xin Jingchao , Zhang Xiaosong , Cao Qinpo , Wang Chaojie , Dai Wenjie , Meng Xiangchuan , Liu Meng , Chang Tonghang , Liu Qingyi , Sun Yuehonga , Ke Yu , Zhang Qiurong , Liu Hongmin . Synthesis and Antitumor Activity Evaluation of 2,4,6-Trisubstituted Pyrimidine Derivatives[J]. Chinese Journal of Organic Chemistry, 2017 , 37(10) : 2725 -2735 . DOI: 10.6023/cjoc201705013
[1] For statistical information about cancer, see:U. S. Food and Drug Administration. http://www.fda.gov/AboutFDA/ReportsManuals-Forms/Reports/ucm276385.htm.
[2] Sangthong, S.; Krusong, K.; Ngamrojanavanich, N.; Vilaivan, T.; Puthong, S.; Chandchawan, S.; Muangsin, N. Bioorg. Med. Chem. Lett. 2011, 21, 4813.
[3] Cao, R. H.; Fan, W. X.; Guo, L.; Ma, Q.; Zhang, G. X.; Li, J. R.; Chen, X. M.; Ren, Z. H.; Qiu, L. Q. Eur. J. Med. Chem. 2013, 60, 135.
[4] Kamal, A.; Tamboli, J. R.; Nayak, V. L.; Adil, S. F.; Vish-nuvardhan, M. V. P. S.; Ramakrishna, S. Bioorg. Med. Chem. Lett. 2013, 23, 3208.
[5] Kamal, A.; Dastagiri, D.; Ramaiah, M. J.; Reddy, J. S.; Bharathi, E. V.; Reddy, M. K.; Sagar, M. V. P.; Reddy, T. L.; Pushpavalli, S. N. C. V. L.; Pal-Bhadra, M. Eur. J. Med. Chem. 2011, 46, 5817.
[6] Hamid, M. K. A. E.; Mihovilovic, M. D.; El-Nassan, H. B. Eur. J. Med. Chem. 2012, 57, 323.
[7] Kassab, A. E.; Gedawy, E. M. Eur. J. Med. Chem. 2013, 63, 224.
[8] Duschinsky, R.; Pleven, E.; Heidelberger, C. J. Am. Chem. Soc. 1957, 79, 4559.
[9] Pecchi, S.; Renhowe, P. A.; Taylor, C.; Kaufman, S.; Merritt, H.; Wiesmann, M.; Shoemaker, K. R.; Knapp, M.; Ornelas, E.; Hendrickson, T. F.; Fantl, W.; Voliva, C. F. Bioorg. Med. Chem. Lett. 2010, 20, 6895.
[10] Keche, A. P.; Hatnapure, G. D.; Tale, R. H.; Rodge, A. H.; Bi-rajdar, S. S.; Kamble, V. M. Bioorg. Med. Chem. Lett. 2012, 22, 3445.
[11] Ni, L.; Meng, C. Q.; Sikorski, J. A. Expert. Opin. Ther. Pat. 2004, 14, 1669.
[12] Dimmock, J. R.; Elias, D. W.; Beazely, M. A. Kandepu, N. M. Curr. Med. Chem. 1999, 6, 1125.
[13] Domínguez, J. N.; León, C.; Rodrigues, J.; Gamboa, D. N.; Gut, J.; Rosenthal, P. J. J. Med. Chem. 2005, 48, 3654.
[14] Gacche, R.; Dhole, N. A.; Kamble, S. G.; Bandgar, B. P. J. En-zyme Inhib. Med. Chem. 2008, 23, 28.
[15] Sharma, V.; Kumar, P.; Pathak, D. J. Heterocycl. Chem. 2010, 47, 491.
[16] Shao, K. P.; Zhang, X. Yao.; Chen, P. J.; Xue, D. Q.; He, P.; Ma, L. Y.; Zheng, J. X.; Zhang, Q. R.; Liu, H. M. Bioorg. Med. Chem. Lett. 2014, 24, 3877.
[17] Chen, P. J.; Yang, A.; Gu, Y. F.; Zhang, X. S.; Shao, K. P.; Xue, D. Q.; He, P.; Jiang, T. F.; Zhang, Q. R.; Liu, H. M. Bioorg. Med. Chem. Lett. 2014, 24, 2741.
[18] Tominaga, H.; Ishiyama, M.; Ohseto, F.; Sasamoto, K.; Hamamoto, T.; Suzuki, K.; Watanabe, M. Anal. Commun. 1999, 36, 47.
/
| 〈 |
|
〉 |
